High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland

S. Regazzoni, G. Marini, A. Grob, A. Pedrazzini, A. Goldhirsch, D. Castelli, F. Cavalli, M. Ghielmini

Research output: Contribution to journalArticle

Abstract

High-dose therapy with bone marrow (BM) or blood stem cell (BSC) support is a high-technology technique usually administered in specialized tertiary centers. The use of BSC has made this technique simpler and accessible also to smaller hospitals. We retrospectively analyzed the data of patients with lymphoma, leukemia and other tumors who received high-dose therapy and BM or BSC transplantation in our district hospital, looking at the type of procedure performed, complications, use of growth factors, and progression-free and overall survival. A total of 40 patients were transplanted over 6 years. No procedure-related deaths and no permanent organ toxicities were seen. The use of BSC brought about a great reduction in the duration of hospital stay, septic complications and transfusion of blood components. For patients with lymphoma (n = 20) the probabilities of progression-free survival and of overall survival at 2 years are 48% (95% C.I. 28-68%) and 68% (95% C.I. 46-84%), respectively. Based on these data, we believe that ABMT and BSC transplantation are feasible and safe in a peripheral hospital when the appropriate human and technical conditions are present. Treatment outcome is then comparable to that of specialized centers.

Original languageEnglish
Pages (from-to)3-7
Number of pages5
JournalBone Marrow Transplantation
Volume19
Issue number1
Publication statusPublished - Jan 1 1997

Fingerprint

Stem Cell Transplantation
Switzerland
Blood Cells
Drug Therapy
Stem Cells
Disease-Free Survival
Lymphoma
Blood Component Transfusion
Bone Marrow
District Hospitals
Length of Stay
Intercellular Signaling Peptides and Proteins
Leukemia
Technology
Survival
Therapeutics
Neoplasms

Keywords

  • High-dose therapy
  • Lymphoma
  • Peripheral hospital
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland. / Regazzoni, S.; Marini, G.; Grob, A.; Pedrazzini, A.; Goldhirsch, A.; Castelli, D.; Cavalli, F.; Ghielmini, M.

In: Bone Marrow Transplantation, Vol. 19, No. 1, 01.01.1997, p. 3-7.

Research output: Contribution to journalArticle

Regazzoni, S. ; Marini, G. ; Grob, A. ; Pedrazzini, A. ; Goldhirsch, A. ; Castelli, D. ; Cavalli, F. ; Ghielmini, M. / High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland. In: Bone Marrow Transplantation. 1997 ; Vol. 19, No. 1. pp. 3-7.
@article{04f33cbf785942af915fdbed3994e199,
title = "High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland",
abstract = "High-dose therapy with bone marrow (BM) or blood stem cell (BSC) support is a high-technology technique usually administered in specialized tertiary centers. The use of BSC has made this technique simpler and accessible also to smaller hospitals. We retrospectively analyzed the data of patients with lymphoma, leukemia and other tumors who received high-dose therapy and BM or BSC transplantation in our district hospital, looking at the type of procedure performed, complications, use of growth factors, and progression-free and overall survival. A total of 40 patients were transplanted over 6 years. No procedure-related deaths and no permanent organ toxicities were seen. The use of BSC brought about a great reduction in the duration of hospital stay, septic complications and transfusion of blood components. For patients with lymphoma (n = 20) the probabilities of progression-free survival and of overall survival at 2 years are 48{\%} (95{\%} C.I. 28-68{\%}) and 68{\%} (95{\%} C.I. 46-84{\%}), respectively. Based on these data, we believe that ABMT and BSC transplantation are feasible and safe in a peripheral hospital when the appropriate human and technical conditions are present. Treatment outcome is then comparable to that of specialized centers.",
keywords = "High-dose therapy, Lymphoma, Peripheral hospital, Stem cell transplantation",
author = "S. Regazzoni and G. Marini and A. Grob and A. Pedrazzini and A. Goldhirsch and D. Castelli and F. Cavalli and M. Ghielmini",
year = "1997",
month = "1",
day = "1",
language = "English",
volume = "19",
pages = "3--7",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland

AU - Regazzoni, S.

AU - Marini, G.

AU - Grob, A.

AU - Pedrazzini, A.

AU - Goldhirsch, A.

AU - Castelli, D.

AU - Cavalli, F.

AU - Ghielmini, M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - High-dose therapy with bone marrow (BM) or blood stem cell (BSC) support is a high-technology technique usually administered in specialized tertiary centers. The use of BSC has made this technique simpler and accessible also to smaller hospitals. We retrospectively analyzed the data of patients with lymphoma, leukemia and other tumors who received high-dose therapy and BM or BSC transplantation in our district hospital, looking at the type of procedure performed, complications, use of growth factors, and progression-free and overall survival. A total of 40 patients were transplanted over 6 years. No procedure-related deaths and no permanent organ toxicities were seen. The use of BSC brought about a great reduction in the duration of hospital stay, septic complications and transfusion of blood components. For patients with lymphoma (n = 20) the probabilities of progression-free survival and of overall survival at 2 years are 48% (95% C.I. 28-68%) and 68% (95% C.I. 46-84%), respectively. Based on these data, we believe that ABMT and BSC transplantation are feasible and safe in a peripheral hospital when the appropriate human and technical conditions are present. Treatment outcome is then comparable to that of specialized centers.

AB - High-dose therapy with bone marrow (BM) or blood stem cell (BSC) support is a high-technology technique usually administered in specialized tertiary centers. The use of BSC has made this technique simpler and accessible also to smaller hospitals. We retrospectively analyzed the data of patients with lymphoma, leukemia and other tumors who received high-dose therapy and BM or BSC transplantation in our district hospital, looking at the type of procedure performed, complications, use of growth factors, and progression-free and overall survival. A total of 40 patients were transplanted over 6 years. No procedure-related deaths and no permanent organ toxicities were seen. The use of BSC brought about a great reduction in the duration of hospital stay, septic complications and transfusion of blood components. For patients with lymphoma (n = 20) the probabilities of progression-free survival and of overall survival at 2 years are 48% (95% C.I. 28-68%) and 68% (95% C.I. 46-84%), respectively. Based on these data, we believe that ABMT and BSC transplantation are feasible and safe in a peripheral hospital when the appropriate human and technical conditions are present. Treatment outcome is then comparable to that of specialized centers.

KW - High-dose therapy

KW - Lymphoma

KW - Peripheral hospital

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0031033228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031033228&partnerID=8YFLogxK

M3 - Article

C2 - 9012924

AN - SCOPUS:0031033228

VL - 19

SP - 3

EP - 7

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -